All In Biotech

Drug Trial Radar · NCT05952596

A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults

A Single-center, Randomized, Active-controlled, Parallel-group, Double-blind, Phase I Clinical Trial to Evaluate Safety and Immunogenicity of Hexavalent Vaccine (APV006) in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

42

Planned (sponsor's estimate)

Start

Jul 17, 2023

Primary completion

Oct 31, 2023

Study completion Mar 31, 2024

Sponsor

Lead sponsor
LG ChemIndustry
Sponsor type
Industry
First posted
Jul 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.

Conditions

  • Diphtheria
  • Tetanus
  • Pertussis
  • Poliomyelitis
  • Hepatitis B
  • Haemophilus Influenzae Type b Infection

Interventions

  • DTaP-HepB-IPV-Hib vaccineBiological

    Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)

  • DTaP-HepB-IPV-Hib vaccineBiological

    Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with immediate reactionsTime frame: For 30 minutes after the vaccination
  2. Number of subjects with solicited adverse eventsTime frame: For 7 days after the vaccination [Day 1-8]
  3. Number of subjects with unsolicited adverse eventsTime frame: For 28 days (+7 days of window period) after the vaccination [Day 1-29]
  4. Number of subjects with serious adverse eventsTime frame: For 181 days (+7 days of window period) after the vaccination [Day 1-181]

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.